Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson and Co.

Becton Dickinson & Co. BDX, +1.70% reported Thursday fiscal fourth-quarter profit and revenue that rose above expectations, with strength in its medical and interventional businesses, and in international sales. Net income for the quarter to Sept.

Becton Dickinson net profit more than doubles, revenue beat expectations

Becton Dickinson & Co. BDX, +1.70% said Thursday it will raise its dividend by nearly 5% and that it set a 10 million share repurchase program that could be valued at nearly $2.5 billion at current prices. The new quarterly dividend of 87 cents a share, up from 83 cents, will be payable Dec. 31 to shareholders of record on Dec. 10.

Becton Dickinson boosts dividend by 5%, sets new repurchase program valued at nearly $2.5 billion

Becton Dickinson and Co (NYSE: BDX) has partnered with Amazon.com Inc (NASDAQ: AMZN) to begin shipment of a new at-home rapid COVID-19 test that can confirm results using an entirely automated smartphone app. The BD Veritor At-Home COVID-19 Test, which U.S. regulators authorized in August, also automatically reports results to federal and state public health authorities.

Becton Dickinson Starts Selling New At-Home Rapid COVID-19 Tests

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?

BD develops, manufactures, and sells medical supplies, laboratory equipment, and diagnostic products among other products.

Becton, Dickinson And Company: R&D And M&A Could Make The Price Spike By 47%

Becton, Dickinson And Co (NYSE: BDX) has received FDA 510(k) clearance for expanded indications for the Rotarex Atherectomy System. Related:   BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance.

BDX's Rotarex Atherectomy System Wins FDA Indication Expansion Approval

Despite a beating the number in the most recent report, this stock has fallen to the lowest Zacks Rank

Bear Of The Day: Becton, Dickinson and Co (BDX)

EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.

BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA

The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE: BDX) BD Veritor At-Home COVID-19 Test. Also Read:   BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV

BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test

Becton Dickinson and Co (NYSE: BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus (HPV). The modular and scalable BD Cor includes an automated sample preparation system, BD Cor PX, and an instrument that automates the BD Onclarity HPV assay, BD Cor GX.

BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV

JPMorgan downgraded Becton Dickinson and Co (NYSE:BDX) to Neutral from Overweight with a price target of $265, down from $280.  While Becton reported better than expected top and bottom-line Q3 results, analyst Robert Marcus tells investors that this was overshadowed by the company's "muted" Q4 and FY22 outlook.

JPMorgan Downgrades Becton Dickinson On Muffled FY22 Outlook

Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.38% and 8.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates

Shares of Becton, Dickinson (NYSE:BDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 24.55% year over year to $2.74, which beat the estimate of $2.44.

Becton, Dickinson: Q3 Earnings Insights

BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.

BD's (BDX) Rapid COVID-19 Test for US Olympic Trial Swimmers

Becton Dickinson and Co (NYSE: BDX) will build a €165 million ($200 million) high-tech manufacturing facility in Zaragoza, Spain, that will create up to 600 jobs by 2030. BD plans to begin constructing the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain.

Becton Dickinson To Build Fourth Facility In Spain To Expand Pre-Filled Drug Delivery Business

, a leading global medical technology company, announced that its Board of Directors have unanimously authorized management to go ahead with a plan to spinoff the Diabetes Care business into an independent, publicly traded company (“NewCo”).

Becton Dickinson To Spin Diabetes Care Unit In 2022

Becton, Dickinson & Co. ( BDX , Financial) delivered another strong top and bottom-line beat when it reported earnings results last week.

Becton, Dickinson & Co. Continues to Shine

Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q2

While reporting financial results for the second fiscal quarter of the year, during which revenues grew more than 15% to $4.9 billion, Becton Dickinson and Co (NYSE: BDX) also laid out its plans to spin off its diabetes-focused segment. Split Highlights: The split is expected to be completed in the first half of 2022, after which the segment will become a completely separate, publicly-traded company, tentatively dubbed “NewCo.”

Becton Dickinson To Spin-Off Diabetes Care Business: Highlights

Becton Dickinson & Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by $480 million in COVID-19 testing sales, and announced plans to separate its Diabetes Care business into an independent publicly traded company. The medical technology company's stock was still inactive in premarket trading.

Becton Dickinson beats profit expectations, plans to spin off Diabetes Care business

Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Becton, Dickinson (BDX)

FRANKLIN LAKES, N.J., April 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, is voluntarily recalling specified lots of the ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator (2% w/w chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) to the user level due to a defective applicator.

BD Announces the Voluntary Recall of Specified Lots of ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator in the United States and U.S. Territories Due to Defective Applicator

Becton, Dickinson is a market leader in multiple medical supply, laboratory, and diagnostic product categories. The company has deleveraged after two major acquisitions and the leverage ratio is now near 2.5X.

News for Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A Stock (BDXA)